Celularity has received funding to support a phase I/II clinical trial of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) for the treatment of COVID-19.
The company was awarded $750,000 by the California Institute for Regenerative Medicine. The funds will be used to evaluate antiviral activities of the cryopreserved product in underserved and disproportionately affected populations with COVID-19.
During the phase I portion, CYNK-001 will be administered intravenously in up to 14 patients in three doses over the course of seven days. Clearance of SARS-CoV-2 and clinical improvement will be evaluated with chest x-ray during the study. The phase II portion will be a randomized, multisite study that will measure multiple doses to determine efficacy and symptom progression.
Celularity received clearance from the U.S. Food and Drug Administration in April to move forward with the study. The University of California, Irvine is the first site to open for patient enrollment.
